BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baekdal J, Krogh J, Klose M, Holmager P, Langer SW, Oturai P, Kjaer A, Federspiel B, Hilsted L, Rehfeld JF, Knigge U, Andreassen M. Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors. Diagnostics (Basel) 2020;10:E881. [PMID: 33138020 DOI: 10.3390/diagnostics10110881] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Nguyen M, Li M, Travers A, Segelov E. Role of Chromogranin A in the Diagnosis and Follow-up of Neuroendocrine Tumors: Real-World Experience. Pancreas 2022;51:1007-10. [PMID: 36607947 DOI: 10.1097/MPA.0000000000002132] [Reference Citation Analysis]
2 Strzelczyk J, Wójcik-giertuga M, Cuber P, Biernacki K, Kos-kudła B, Strzelczyk JK, Gagat M. Assessment of the Concentration of Endogenous Factors Regulating Angiogenesis, VASH-1 and VEGF-A, in the Blood Serum of Patients with Neuroendocrine Neoplasms. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/9084393] [Reference Citation Analysis]
3 van Balveren JA, Erdem-eraslan L, Phg Verboeket-van de Venne W, Jm Doggen C, Hofland J, Oosterhuis WP, de Rijke YB, Mj Hoedemakers R, Kusters R. Awareness of drug laboratory test interactions is important for prevention of unnecessary additional diagnostics: an example. Clinica Chimica Acta 2022. [DOI: 10.1016/j.cca.2022.03.013] [Reference Citation Analysis]
4 Ciobanu OA, Martin S, Fica S. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). Exp Ther Med 2021;22:1479. [PMID: 34765020 DOI: 10.3892/etm.2021.10914] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]